Last reviewed 2026-04-20 · How we verify

PF-07852352 Influenza saRNA 1 (pf-07852352-influenza-sarna-1)

Pfizer · FDA-approved active Quality 35/100

PF-07852352 Influenza saRNA 1 (generic name: pf-07852352-influenza-sarna-1) is a antisense oligonucleotide drug developed by Pfizer. It is currently FDA-approved for Influenza.

PF-07852352 Influenza saRNA 1, marketed by Pfizer, is an influenza vaccine with a key composition patent expiring in 2028. Its primary competitive advantage lies in its established market presence, though the specific mechanism of action remains undisclosed. The main threat to PF-07852352 Influenza saRNA 1 comes from competing mRNA and taRNA vaccine candidates, as well as vaccines for other viral diseases like SARS-CoV-2 and Zika, which may divert market attention and resources.

At a glance

Generic name	pf-07852352-influenza-sarna-1
Sponsor	Pfizer
Drug class	antisense oligonucleotide
Target	influenza virus
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

Influenza

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Darunavir
Lopinavir
Ritonavir
Saquinavir

Key clinical trials

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07852352 Influenza saRNA 1 CI brief — competitive landscape report
PF-07852352 Influenza saRNA 1 updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about PF-07852352 Influenza saRNA 1

What is PF-07852352 Influenza saRNA 1?

PF-07852352 Influenza saRNA 1 (pf-07852352-influenza-sarna-1) is a antisense oligonucleotide drug developed by Pfizer, indicated for Influenza.

What is PF-07852352 Influenza saRNA 1 used for?

PF-07852352 Influenza saRNA 1 is indicated for Influenza.

Who makes PF-07852352 Influenza saRNA 1?

PF-07852352 Influenza saRNA 1 is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of PF-07852352 Influenza saRNA 1?

pf-07852352-influenza-sarna-1 is the generic (nonproprietary) name of PF-07852352 Influenza saRNA 1.

What drug class is PF-07852352 Influenza saRNA 1 in?

PF-07852352 Influenza saRNA 1 belongs to the antisense oligonucleotide class. See all antisense oligonucleotide drugs at /class/antisense-oligonucleotide.

What development phase is PF-07852352 Influenza saRNA 1 in?

PF-07852352 Influenza saRNA 1 is FDA-approved (marketed).

What does PF-07852352 Influenza saRNA 1 target?

PF-07852352 Influenza saRNA 1 targets influenza virus and is a antisense oligonucleotide.

Drug class: All antisense oligonucleotide drugs
Target: All drugs targeting influenza virus
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for Influenza
Compare: PF-07852352 Influenza saRNA 1 vs similar drugs
Pricing: PF-07852352 Influenza saRNA 1 cost, discount & access